

Generic Name: Brand Name Medication

Preferred: N/A

Therapeutic Class or Brand Name: Brand Name Medication

Non-preferred: N/A

Applicable Drugs (if Therapeutic Class): N/A

Date of Origin: 2/1/2013

GPI Code: Various

Date Last Reviewed / Revised: 8/1/2019

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I is met)

- I. Patient has a physician evaluated, charted documentation of an allergic reaction or adverse reaction to a generic therapeutic equivalent. Patient complaints of lack of efficacy are not acceptable reasons for failure such as "Client said", "client reports", "doesn't work", or "causes nausea". The following A and B must be provided:
 - A. Details as to why a generic therapeutic equivalent is not appropriate or is contraindicated.
 - B. Explanation of why treatment with the specific branded product is necessary.

EXCLUSION CRITERIA

- N/A

OTHER CRITERIA

- Many extended-release branded products do not have extended-release generic equivalents. In these cases, an adequate trial of the short-acting generic product is required.
- Some brand name dosage forms may not have the same dosage form available in a generic therapeutic equivalent. In these cases, an adequate trial of the other available dosage forms of the generic therapeutic equivalent is required.

QUANTITY / DAYS SUPPLY RESTRICTIONS

- Quantity/Days Supply Restrictions may apply.

APPROVAL LENGTH

- **Authorization:** 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing the medication is effective.

APPENDIX

N/A

REFERENCES

1. U.S. Food and Drug Administration (FDA). Generic Drugs. Last updated May 2019. Available at: <https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs>.

HISTORICAL TRACKING OF CHANGES MADE TO POLICY

Date	Notes/Changes
8/1/2019	<ol style="list-style-type: none"> 1. Removed "https://medicaid.utah.gov/pharmacy/priorauthorization/pdf/Brand%20Name.pdf." Added "https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs" under References.
12/4/2018	<ol style="list-style-type: none"> 1. Removed "https://medicaid.utah.gov/pharmacy/priorauthorization/pdf/BrandNameMedication.pdf." Added "https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru265reg.pdf" under References.
1/4/2018	<ol style="list-style-type: none"> 1. Policy reviewed: no changes made.
10/9/2018	<ol style="list-style-type: none"> 1. Policy reviewed: no changes made.
8/20/2015	<ol style="list-style-type: none"> 1. Changed "See attached "Brand Name Medications Requiring Therapeutic Equivalent Generics First" list. Policy may also apply to other medications not listed" to "Policy may apply to any brand name medication that has a generic therapeutic equivalent available" under Applicable Drugs. 2. Changed Appendix from "See attached "Brand Name Medications Requiring Therapeutic Equivalent Generics First" list" to "N/A". 3. Deleted "Brand Name Medications Requiring Therapeutic Equivalent Generics First" list. 4. Updated "http://www.health.utah.gov/medicaid/pharmacy/priorauthorization/pdf/Brand_Name_Medication.pdf." to "https://medicaid.utah.gov/pharmacy/priorauthorization/pdf/BrandNameMedication.pdf" under References.
12/10/2013	<ol style="list-style-type: none"> 1. Adapted policy to new format. 2. Added "Various" to GPI Code. 3. Changed Prior Authorization Criteria from: "Prior Authorization Criteria: Details as to why a generic therapeutic equivalent is not appropriate or is contraindicated AND Explanation of why treatment with the specific branded product is necessary; Covered Uses: Prior authorizations for brand name medications require physician evaluated, charted documentation of an allergic reaction or adverse reaction. Patient complaints of lack of efficacy are not acceptable reasons for failure such as "Client said", "client reports", "doesn't work", or "causes nausea" to: "Patient has a physician evaluated, charted documentation of an allergic reaction or adverse reaction to a generic therapeutic equivalent. Patient complaints of lack of efficacy are not acceptable reasons for failure such as "Client said", "client reports", "doesn't work", or "causes nausea". The following A and B must be provided: A. Details as to

	<p>why a generic therapeutic equivalent is not appropriate or is contraindicated, B. Explanation of why treatment with the specific branded product is necessary”.</p> <ol style="list-style-type: none"> 4. Changed Re-Authorization under Approval Length from “Updated letter of medical necessity” to “An updated letter of medical necessity or progress notes showing the medication is effective”. 5. Added “Aczone® (dapsone), Armour® Thyroid (thyroid), Bactroban® (mupirocin), Boniva® (ibandronate), Cipro® (ciprofloxacin), Cipro® XR (ciprofloxacin), Colcrys® (colchicine), Coumadin® (warfarin), Lanoxin® (digoxin), Levothroid® (levothyroxine), Levoxyl® (levothyroxine), Plavix® (clopidogrel), Prevpac® (lansoprazole/amoxicillin/clarithromycin), Sonata® (zaleplon), Synthroid® (levothyroxine)” to the “Brand Name Medications Requiring Therapeutic Equivalent Generics First” list. 6. Removed “Alphagan-P® (brimonidine), Prevacid (lansoprazole), Prevacid® SoluTab (lansoprazole), Prevacid® Solution (lansoprazole), Prevacid® 24HR (lansoprazole), Protonix® (pantoprazole)” to the “Brand Name Medications Requiring Therapeutic Equivalent Generics First” list.
--	---

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.